American Association for Cancer Research

Program

Bookmark and Share

Advances in Breast Cancer Research 2011

Wednesday, October 12

Opening Keynote Address

Session Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
7:00 p.m.-8:00 p.m.

Protective adaptive responses to targeted cancer therapies
Joan S. Brugge, Harvard Medical School, Boston, MA

Networking Reception

8:00 p.m.-9:30 p.m.

Thursday, October 13

Continental Breakfast

7:30 a.m.-8:30 a.m.

Session 1: Genomics / Epigenomics

Session Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
8:30 a.m.-10:30 a.m.

Parity-associated changes in the human breast and their relevance to breast cancer
Kornelia Polyak

Integrated molecular profiles of primary breast tumors: Improved prognostic power
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Institute for Cancer Research, Oslo, Norway

Breast cancer epigenetics: From DNA methylation to non-coding RNAs
Manel Esteller, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain

Systems epigenomics for prognosis and personalized treatment
Tim Hui-Ming Huang, Ohio State University Comprehensive Cancer Center, Columbus, OH

Break

10:30 a.m.-11:00 a.m.

Session 2: Metabolomics

Session Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
11:00 a.m.-12:30 p.m.

PI 3-Kinase and cancer cell metabolism
Lewis C. Cantley

Nutrient addiction in the breast: Strong subtype-specific activities and potential therapeutic opportunities
Luika Timmerman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Mechanisms involved in reduction in risk of breast cancer by metformin and similar compounds
Michael Pollak, McGill University, Montreal, QC, Canada

Lunch on own / Free time

12:30 p.m.-2:30 p.m.

Session 3: Targeted Therapies (HER2, PIK3CA, Basal-like)

Session Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA
2:30 p.m.-4:30 p.m.

Targeting the PI3K/mTOR pathway in breast cancer
José Baselga

Targeting IGF signaling in breast cancer subtypes
Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Targeting HER2: Current and future approaches
Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA

Basal-like breast cancer: What is the target?
Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Dinner on own / Free time

4:30 p.m.-7:00 p.m.

Poster Session A / Reception

7:00 p.m.-10:00 p.m.

Friday, October 14

Continental Breakfast

7:30 a.m.-8:30 a.m.

Session 4: Inflammation and Cancer as Systemic Disease

Session Chairperson: Patricia S. Steeg, National Cancer Institute, Bethesda, MD
8:30 a.m.-10:30 a.m.

Title to be announced
Lisa M. Coussens, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA

The breast tumour microenvironment, tumour heterogeneity and clinical outcome
Morag Park, Canadian Institutes of Health Research, Montréal, QC, Canada

Tumor entrained neutrophils inhibit seeding in the pre-metastatic lung
Robert Benezra, Memorial Sloan-Kettering Cancer Center, New York, NY

A LPA1 antagonist, Debio 0719, inhibits breast cancer metastasis and induces dormancy
Patricia S. Steeg

Break

10:30 a.m.-11:00 a.m.

Session 5: Non-Coding RNAs

Session Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
11:00 a.m.-12:30 p.m.

Long noncoding RNAs in breast cancer progression
Howard Y. Chang, Stanford University, Stanford, CA

The role of non-coding RNA regulators of self renewal in cancer
Michael F. Clarke, Stanford University School of Medicine, Palo Alto, CA

The dodecalogus of non-coding RNAs involvement in breast cancer: 2011 version
George A. Calin, University of Texas MD Anderson Cancer Center, Houston, TX

Poster Session B / Lunch

12:30 p.m.-3:30 p.m.

Session 6: Stem Cells

Session Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
3:30 p.m.-5:00 p.m.

EMT programs and therapeutic resistance of breast cancer stem cells
Jeffrey M. Rosen

Phenotypic and functional characterization of the mammary luminal epithelial cell hierarchy
John P. Stingl, Cancer Research UK Cambridge Research Institute, Cambridge, England

Mammary stem cell niche and implications for breast cancer
Rama Khokha, University of Toronto, Ontario Cancer Institute, Toronto, ON, Canada

Panel Discussion
Transforming Translational Research: Innovation through Collaboration Between Women and Scientists

Presented by The Love/Avon Army of Women
5:00 p.m.-6:00 p.m.

    Panelists:
  • Susan M. Love, Dr. Susan Love Research Foundation, Santa Monica, CA
  • Jennifer L. Ivanovich, Washington University School of Medicine, St. Louis, MO
  • Thea D. Tlsty, University of California School of Medicine, San Francisco, CA
  • Leslie Bernstein, City of Hope, Duarte, CA

The Love/Avon Army of Women has existed for three years. This panel will focus on how the Army of Women has accelerated research into the cause and prevention of breast cancer and how the scientific community can best utilize the Army of Women for their research needs. Dr. Susan Love will discuss the overall vision for the initiative, some of the success stories, and the benefits of designing a study that will utilize the Army of Women cohort. Ms. Ivanovich has used the Army of Women for her genomic study and can discuss how this resource has accelerated their research and enabled them to save money, time and resources. Dr. Tlsty will discuss how the Army of Women is revolutionizing the way biologists do breast cancer research. Dr. Bernstein will discuss the importance of this resource in the scientific community and how it can move breast cancer beyond a cure to understanding cause and prevention.

Dinner on own / Evening off

6:00 p.m.-

Saturday, October 15

Continental Breakfast

7:30 a.m.-8:30 a.m.

Keynote Address

Session Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
8:30 a.m.-9:30 a.m.

Title to be announced
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Break

9:30 a.m.-10:00 a.m.

Session 7: Endocrine Resistance

Session Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA
10:00 a.m.-11:30 a.m.

Epigenetic and cistromic determinants of endocrine dependence
Myles Brown, Dana-Farber Cancer Institute, Boston, MA

Endocrine resistance: Insights from next gen sequencing
Matthew J. Ellis, Washington University Siteman Cancer Center, St. Louis, MO

Escape pathways contributing to endocrine resistance in breast cancer
C. Kent Osborne, Baylor College of Medicine Cancer Center, Houston, TX

Departure